Creative Medical Technology Holdings, Inc. announced compelling mid-term follow-up data from its StemSpine® pilot study, which utilizes AlloStem™ cells for the treatment of chronic lower back pain. The pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility.
Notably, over 90% of patients reported no opioid use for pain management three years post-procedure. The study also showed an 80% persistent reduction in pain scores and a greater than 60% improvement in Oswestry Disability Index scores. Only one patient required reintervention at the three-year follow-up mark, and no serious adverse events were reported.
These results underscore the safety and clinical efficacy of AlloStem™ in the StemSpine® procedure by promoting repair, remodeling, and improved vascularization in affected areas. This promising data supports the company's vision of providing innovative, non-surgical solutions for millions of Americans struggling with chronic lower back pain, and continues to drive enrollment in the ongoing FDA-cleared Phase 1/2 ADAPT clinical trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.